RT Journal Article
SR Electronic
T1 Epidemiology, Clinico-Pathological Characteristics, and Comorbidities of SARS-CoV-2 infected Pakistani Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.25.21264111
DO 10.1101/2021.09.25.21264111
A1 Omer, Saadia
A1 Sarwar, Muhammad Bilal
A1 Roman, Muhammad
A1 Usman, Muhammad
A1 Alam, Muhammad
A1 Afzal, Nadeem
A1 Qaiser, Tanveer Ahmed
A1 Yasir, Muhammad
A1 Shahzad, Faheem
A1 Tahir, Romeeza
A1 Ayub, Saima
A1 Akram, Javid
A1 Jahan, Shah
YR 2021
UL http://medrxiv.org/content/early/2021/09/27/2021.09.25.21264111.abstract
AB SARS-CoV-2 is a causative agent for COVI-19 disease, initially reported from Wuhan, China. Infected Patients experienced mild to severe symptoms, resulting in several fatalities due to a weak understanding of its pathogenesis, which is the same even to date. This cross-sectional study has been designed on four hundred and fifty-two symptomatic, mild-to-moderate, and severe/critical patients to understand the epidemiology and clinical characteristics of COVID-19 patients with their comorbidities and response to treatment. The mean age of studied patients was (58±14.42) years, and the overall male to female ratio was 61.7 to 38.2%, respectively. 27.3% of the patients had a history of exposure, 11.9% travel history, while for 60% of patients, the source of infection was unknown. The most prevalent signs and symptoms in ICU patients were dry coughs, myalgias, shortness of breath, gastrointestinal discomfort, and abnormal Chest X-ray (p<0.001), along with the high percentage of hypertension (p=0.007) and COPD (p=0.029) as leading comorbidities. Complete Blood Counts indicators were significantly increased in severe patients, while the Coagulation Profile and D-dimer values were significantly higher in mild-to-moderate (non-ICU) patients (p < 0.001). Serum Creatinine (1.22 umole L-1; p = 0.016) and LDH (619 umol L-1; p < 0.001) indicators were significantly high in non-ICU patients while, raised values of Total Bilirubin (0.91 umol L-1; p = 0.054), CRP (84.68 mg L-1; p = 0.001) and Ferritin (996.81 mg L-1; p < 0.001) were found in ICU patients. Drug Dexamethasone was the leading prescribed and administrated medicine to the COVID-19 patients, followed by Remdesivir, Meropenem, Heparin, and Tocilizumab, respectively. A characteristic pattern of Ground glass opacities (GGO), consolidation, and interlobular septal thickening were prominent in severely infected patients. These findings could be used for future research, control, and prevention of SARS-CoV-2 infected patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot Applicable for this studyFunding StatementThis study is part of the Rapid COVID Project (RRG# 211) funded by the Higher Education Commission (HEC) and the World Bank. The authors duly acknowledged the hospital administrations' support, patients, and their families who participated in this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was conducted under approval number UHS/REG-20/ERC/1758 from the University of Health Sciences Lahore Ethical Review Committee. Written informed consents were provided by the patients/participants to participate in this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data generated by this study are used in the manuscript. no supplementary data are generated.